ΠΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² Π-ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ·Π°
ΠΠ΅ΠΉΠΊΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ ΠΏΡΠΈ ΡΠ°Π·Π½ΡΡ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π²Π°ΡΠΈΠ°Π½ΡΠ°Ρ Π-Π₯ΠΠ ΠΈΠΌΠ΅Π»ΠΈ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠ°. ΠΡΠΈ Π°ΡΠΈΠΏΠΈΡΠ½ΠΎΠΌ ΠΏΠΎΠ΄Π²Π°ΡΠΈΠ°Π½ΡΠ΅ Π-Π₯ΠΠ. ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΡΠΈΠΏΠΈΡΠ½ΡΠΌ Π²Π°ΡΠΈΠ°Π½ΡΠΎΠΌ ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΎΡΡ Π·Π½Π°ΡΠΈΠΌΠΎΠ΅ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΠΎΠ³ΠΎ Π°Π½ΡΠΈΠ³Π΅Π½Π° CD38 (53,8±3,2 ΠΏΡΠΎΡΠΈΠ² 42,3±3,8, Ρ=0,027). ΠΡΠΈ Π°ΡΠΈΠΏΠΈΡΠ½ΠΎΠΌ ΠΏΠΎΠ΄Π²Π°ΡΠΈΠ°Π½ΡΠ΅ ΡΠΈΡΠ»ΠΎ Π‘038-ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΡΡ ΡΠ»ΡΡΠ°Π΅Π² (37,5%) Π±ΡΠ»ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π²ΡΡΠ΅ (Ρ=0,041) ΡΠ΅ΠΌ ΠΏΡΠΈ… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΠ»Π°Π²Π° 1. ΠΠΠΠΠ ΠΠΠ’ΠΠ ΠΠ’Π£Π Π«
- 1. 1. ΠΡΡΠΎΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ, ΡΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡ, ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΡ
- 1. 2. ΠΠ½ΡΠΎΠ³Π΅Π½Π΅Π· Π-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΈ Π-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠ΅ Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΡΠ΅ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ
- 1. 3. ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° Π-Π₯ΠΠ
- 1. 4. ΠΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π-Π₯ΠΠ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠ°Π·Π½ΡΡ Π²ΠΎΠ·ΡΠ°ΡΡΠ½ΡΡ Π³ΡΡΠΏΠΏ
- ΠΠ»Π°Π²Π° 2. ΠΠΠ’ΠΠ ΠΠΠΠ« Π ΠΠΠ’ΠΠΠ«
- ΠΠ»Π°Π²Π° 3. Π ΠΠΠ£ΠΠ¬Π’ΠΠ’Π« ΠΠ‘Π‘ΠΠΠΠΠΠΠΠΠ―
- 3. 1. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΡΡ ΡΠ»Π΅ΠΌΠ΅Π½ΡΠΎΠ² ΠΏΡΠΈ ΡΠ°Π·Π½ΡΡ Π²Π°ΡΠΈΠ°Π½ Π³Π°Ρ Π-Π₯ΠΠ
- 3. 2. ΠΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠΈΡΠ΅ΡΠΊΠ°Ρ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΡΡ ΡΠ»Π΅ΠΌΠ΅Π½ΡΠΎΠ² ΠΏΡΠΈ ΡΠ°Π·Π½ΡΡ Π²Π°ΡΠΈΠ°Π½ΡΠ°Ρ Π-Π₯ΠΠ
- 3. 3. Π₯Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° ΠΊΡΠΎΠ²Π΅ΡΠ²ΠΎΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΏΡΠΈ ΡΠ°Π·Π½ΡΡ Π²Π°ΡΠΈΠ°Π½ΡΠ°Ρ Π-Π₯ΠΠ
- 3. 4. Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½Π°Ρ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΊΡΠΎΠ²Π΅ΡΠ²ΠΎΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ Π-Π₯ΠΠ ΡΠ°Π·Π½ΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ°
- ΠΠ»Π°Π²Π° 4. ΠΠΠ‘Π£ΠΠΠΠΠΠ
- ΠΠ«ΠΠΠΠ«
ΠΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² Π-ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ·Π° (ΡΠ΅ΡΠ΅ΡΠ°Ρ, ΠΊΡΡΡΠΎΠ²Π°Ρ, Π΄ΠΈΠΏΠ»ΠΎΠΌ, ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ)
Π-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΉ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ·/Π»ΠΈΠΌΡΠΎΠΌΠ° ΠΈΠ· ΠΌΠ°Π»ΡΡ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² (B-XJIJI) ΠΎΡΠ½ΠΎΡΠΈΡΡΡ ΠΊ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡΠΌ ΠΈΠ· Π·ΡΠ΅Π»ΡΡ Π-ΠΊΠ»Π΅ΡΠΎΠΊ (ΠΠΠ, 2008) [136].
ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΡΡΠΈΡΠ°ΡΡ B-XJTJI Π½Π΅ΠΎΠ΄Π½ΠΎΡΠΎΠ΄Π½ΡΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ΠΌ, ΠΈΠΌΠ΅ΡΡΠΈΠΌ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²ΠΎ ΡΠΎΡΠΌ Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΉ, Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΈ ΠΎΡΠ²Π΅ΡΠΎΠΌ Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡ [3,4].
Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½Π°Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° Π-Π₯ΠΠ ΠΎΡΠ½ΠΎΠ²Π°Π½Π° Π½Π° ΡΠΎΠ²ΠΌΠ΅ΡΡΠ½ΠΎΠΌ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΡΠΈΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² ΠΊΠ»Π΅ΡΠΎΠΊ Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΠΎΠ³ΠΎ ΡΡΠ΄Π° Π² Π€ΠΠ-ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ (Bennet J.M., 1989) Π²ΡΠ΄Π΅Π»ΡΡΡΡΡ Π΄Π²Π° ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π²Π°ΡΠΈΠ°Π½ΡΠ° B-XJIJI: ΡΠΈΠΏΠΈΡΠ½ΡΠΉ, ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΡΠΉ ΠΎΠ΄Π½ΠΎΠΎΠ±ΡΠ°Π·Π½ΡΠΌΠΈ Π½Π΅Π±ΠΎΠ»ΡΡΠΈΠΌΠΈ Π»ΠΈΠΌΡΠΎΡΠΈΡΠ°ΠΌΠΈ, ΠΈ ΡΠΌΠ΅ΡΠ°Π½Π½ΠΎ-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΉ, Π² ΠΊΠΎΡΠΎΡΠΎΠΌ ΡΡΠ±ΡΡΡΠ°Ρ ΠΎΠΏΡΡ ΠΎΠ»ΠΈ Π½Π΅ΠΎΠ΄Π½ΠΎΡΠΎΠ΄Π΅Π½ ΠΈ ΡΠΎΡΡΠΎΠΈΡ ΠΈΠ· Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΡΠΈΠ·Π½Π°ΠΊΠ°ΠΌΠΈ [21].
Π‘ ΠΏΠΎΠΌΠΎΡΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π° ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏ Π»Π΅ΠΉ-ΠΊΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΊΠ»ΠΎΠ½Π° Π-Π₯ΠΠ: CD 19+, CD5+, CD23+, CD20-/+ ΠΈ CD21+. ΠΠ° ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΡ Π»ΠΈΠΌΡΠΎΡΠΈΡΠ°Ρ ΠΏΡΠΈ B-XJIJI Π²Π°ΡΠΈΠ°Π±Π΅Π»ΡΠ½ΠΎ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ Π°Π½ΡΠΈΠ³Π΅Π½ CD38, ΡΠ²Π»ΡΡΡΠΈΠΉΡΡ Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΡΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ, Π½Π΅Π³Π°ΡΠΈΠ²Π½ΠΎ Π²Π»ΠΈΡΡΡΠΈΠΌ Π½Π° ΠΏΡΠΎΠ³Π½ΠΎΠ· B-XJIJI (ΠΡΠ³ΠΎΠ²ΡΠΊΠ°Ρ Π‘.Π., ΠΠΎΡΡΠ°ΡΡ Π. Π., Π’ΡΠΏΠΈΡΡΠ½ Π. Π., 2005) [7].
ΠΡΡΠ²Π»Π΅Π½Π° Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΡΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΡΡΠ±ΡΡΡΠ°ΡΠ° ΠΎΠΏΡΡ ΠΎΠ»ΠΈ ΠΏΡΠΈ Π-Π₯ΠΠ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΠΌΡΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΡΡΠ°ΡΡΡΠ° IgVh Π³Π΅Π½ΠΎΠ².
ΠΠΎΠΏΡΠΎΡΡ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠΈ-ΡΠ΅ΡΠΊΠΈΡ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² ΠΏΡΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ Π²Π°ΡΠΈΠ°Π½ΡΠ°Ρ Π-Π₯ΠΠ ΠΎΡΡΠ°ΡΡΡΡ Π΄ΠΎ Π½Π°ΡΡΠΎΡΡΠ΅Π³ΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ ΡΠΏΠΎΡΠ½ΡΠΌΠΈ. ΠΠ΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΠΈΠ·ΡΡΠ΅Π½Π½ΠΎΠΉ ΠΎΡΡΠ°Π΅ΡΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΏΡΠΈ ΡΠ°Π·Π½ΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠΈΠΏΠ°Ρ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ²: Ρ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ ΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ΠΌ Π°Π½ΡΠΈΠ³Π΅Π½Π° CD38, Ρ ΡΠ°Π·Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΈ ΡΡΠ΅ΠΏΠ΅Π½ΡΡ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π-Π°Π½ΡΠΈΠ³Π΅Π½ΠΎΠ²: CD20, CD21. ΠΠ½ΡΠ΅ΡΠ΅ΡΠ½ΡΠΌ Π΄Π»Ρ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ°ΠΊΠΆΠ΅ Π²ΠΎΠΏΡΠΎΡ Π²Π·Π°ΠΈΠΌΠΎΠ·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ , ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠΈΡΠ΅ΡΠΊΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΠΏΡΠ»Π° ΠΈ Π΄Π°Π½Π½ΡΡ ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΠ³ΠΎ Π³Π΅ΠΌΠΎΠΏΠΎΡΠ·Π°: ΡΡΠΎΠ²Π½Ρ Π³Π΅ΠΌΠΎΠ³Π»ΠΎΠ±ΠΈΠ½Π°, ΡΠΈΡΠ»Π° ΡΡΠΈΡΡΠΎΡΠΈΡΠΎΠ², Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠΎΠ², ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠΎΠ², ΠΈΠΌΠ΅ΡΡΠΈΡ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π΄Π»Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π-Π₯ΠΠ (ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ Binet).
ΠΠ΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΠΌΠΈ ΡΠ²Π»ΡΡΡΡΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΈΠΌ-ΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠ° Π»Π΅ΠΉΠΊΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π-Π₯ΠΠ ΡΠ°Π·Π½ΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ°. Π‘ ΡΡΡΡΠΎΠΌ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ Π»Π΅ΠΉΠΊΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΊΠ»ΠΎΠ½Π° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠ°Π·Π½ΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ Π½Π΅ΡΠΎΠΌΠ½Π΅Π½Π½ΡΠΉ ΠΈΠ½ΡΠ΅ΡΠ΅Ρ.
Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½Π½Π°Ρ Π½Π° ΡΠ΅Π³ΠΎΠ΄Π½ΡΡΠ½Π΅ΠΉ Π΄Π΅Π½Ρ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΏΠΎ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ°Π·Π½ΠΎΡΠΎΠ΄Π½ΠΎΡΡΠΈ Π-Π₯ΠΠ Π΄Π΅Π»Π°Π΅Ρ Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΡΠΌ Π΄Π΅ΡΠ°Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΌΠΎΡΡΠΎΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ Π»Π΅ΠΉΠΊΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ ΠΏΡΠΈ Π-Π₯ΠΠ Π΄Π»Ρ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ Π²Π°ΡΠΈΠ°Π½ΡΠ° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ.
Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ.
ΠΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ Π·Π°ΠΊΠΎΠ½ΠΎΠΌΠ΅ΡΠ½ΡΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² ΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΊΡΠΎΠ²Π΅ΡΠ²ΠΎΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠ°Π·Π½ΡΠΌΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π²Π°ΡΠΈΠ°Π½ΡΠ°ΠΌΠΈ Π-Π₯ΠΠ.
ΠΠ°Π΄Π°ΡΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ.
1. ΠΡ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΎΠ²Π°ΡΡ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π»Π΅ΠΉΠΊΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ Π»ΠΈΠΌ-ΡΠΎΠΈΠ΄Π½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΠΎΠ΄ΡΡΡΡΠ° Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ³ΡΠ°ΠΌΠΌ. Π£ΡΡΠ°Π½ΠΎΠ²ΠΈΡΡ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΡ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² Π-Π₯ΠΠ.
2. ΠΡΠ΅Π½ΠΈΡΡ ΠΈΠΌΠΌΡΠ½Π½ΡΠΉ ΠΏΡΠΎΡΠΈΠ»Ρ Π-Π»Π΅ΠΉΠΊΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΡΡ ΡΠ»Π΅ΠΌΠ΅Π½ΡΠΎΠ² ΠΏΡΠΈ ΡΠ°Π·Π½ΡΡ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π²Π°ΡΠΈΠ°Π½ΡΠ°Ρ Π-Π₯ΠΠ ΠΈ ΠΏΡΠΎΠ²Π΅ΡΡΠΈ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠΈΡΠ΅ΡΠΊΠΈΡ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΏΡΠΈ ΡΠ°Π·Π½ΡΡ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π²Π°ΡΠΈΠ°Π½ΡΠ°Ρ Π-Π₯ΠΠ.
3. ΠΡΠΎΠ²Π΅ΡΡΠΈ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈ-ΠΏΠΈΡΠ΅ΡΠΊΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΏΡΠΈ ΡΠ°Π·Π½ΡΡ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π²Π°ΡΠΈΠ°Π½ΡΠ°Ρ B-XJIJT.
4. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΡ ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ ΠΊΡΠΎΠ²Π΅ΡΠ²ΠΎΡΠ΅Π½ΠΈΡ ΠΏΠΎ Π΄Π°Π½Π½ΡΠΌ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ ΠΈ Π°ΡΠΏΠΈΡΠ°ΡΠ° ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠ°Π·Π½ΡΠΌΠΈ Π²Π°ΡΠΈΠ°Π½ΡΠ°ΠΌΠΈ B-XJTJI.
5. ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°ΡΡ ΡΠ°ΡΡΠΎΡΡ ΡΠ°Π·Π½ΡΡ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² B-XJIJI, ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠ° Π»Π΅ΠΉΠΊΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ ΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΊΡΠΎΠ²Π΅ΡΠ²ΠΎΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ Π² ΡΠ°Π·Π½ΡΡ Π²ΠΎΠ·ΡΠ°ΡΡΠ½ΡΡ Π³ΡΡΠΏΠΏΠ°Ρ .
ΠΠ°ΡΡΠ½Π°Ρ Π½ΠΎΠ²ΠΈΠ·Π½Π°.
ΠΠΏΠ΅ΡΠ²ΡΠ΅ Π΄Π°Π½Π° Π΄Π΅ΡΠ°Π»ΡΠ½Π°Ρ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ Π»Π΅ΠΉΠΊΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΏΡΠΈ B-XJIJ1 Ρ ΠΏΠΎΠ΄ΡΡΡΡΠΎΠΌ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ³ΡΠ°ΠΌΠΌ ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π°. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΡ Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² B-XJIJI: ΡΠΈΠΏΠΈΡΠ½ΠΎΠ³ΠΎ ΠΈ ΡΠΌΠ΅ΡΠ°Π½Π½ΠΎ-ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ Ρ Π΄Π²ΡΠΌΡ ΠΏΠΎΠ΄Π²Π°ΡΠΈΠ°Π½ΡΠ°ΠΌΠΈ — Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ·ΠΎΠΌ/ΠΏΡΠΎΠ»ΠΈΠΌΡΠΎΡΠΈΡΠ°ΡΠ½ΡΠΌ Π»Π΅ΠΉΠΊΠΎΠ·ΠΎΠΌ (Π₯ΠΠ/ΠΠ) ΠΈ Π°ΡΠΈΠΏΠΈΡΠ½ΡΠΌ. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Π² Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π΅ ΡΠ»ΡΡΠ°Π΅Π² ΠΏΡΠΈ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π²Π°ΡΠΈΠ°Π½Ρ Π-Π₯ΠΠ ΠΎΡΡΠ°Π΅ΡΡΡ ΡΡΠ°Π±ΠΈΠ»ΡΠ½ΡΠΌ ΠΈ Π»ΠΈΡΡ Π² ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΡ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅ΡΡΡ Π΅Π³ΠΎ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅, ΠΏΡΠΈΡΡΠΌ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΡΠΌ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΠ΅ΡΠ΅Ρ ΠΎΠ΄ ΡΠΈΠΏΠΈΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²Π°ΡΠΈΠ°Π½ΡΠ° Π² Π°ΡΠΈΠΏΠΈΡΠ½ΡΠΉ ΠΏΠΎΠ΄Π²Π°ΡΠΈΠ°Π½Ρ.
ΠΡΡΠ²Π»Π΅Π½Ρ ΡΠ°Π·Π»ΠΈΡΠΈΡ Π² Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΡ Π»Π΅ΠΉΠΊΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΏΡΠΈ ΡΠ°Π·Π½ΡΡ Π²Π°ΡΠΈΠ°Π½ΡΠ°Ρ Π-Π₯ΠΠ. ΠΡΠΈ Π°ΡΠΈΠΏΠΈΡΠ½ΠΎΠΌ ΠΏΠΎΠ΄Π²Π°ΡΠΈΠ°Π½ΡΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π°Π½ΡΠΈΠ³Π΅Π½Π° CD5 ΠΈ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠΊΠ΅ΡΠ° CD38 ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈΡΡ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΡΠ°ΡΠ΅, ΡΠ΅ΠΌ Π² ΠΎΡΡΠ°Π»ΡΠ½ΡΡ ΡΠ»ΡΡΠ°ΡΡ . ΠΠ»Ρ Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΏΡΠΈ Π₯ΠΠ/ΠΠ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΡΠΌ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠΌ ΡΠ²ΠΈΠ»Π°ΡΡ Π²ΡΡΠΎΠΊΠ°Ρ ΡΠ°ΡΡΠΎΡΠ° ΡΠ»ΡΡΠ°Π΅Π² Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π°Π½ΡΠΈΠ³Π΅Π½Π° CD20. ΠΡΠΈ ΡΠΈΠΏΠΈΡΠ½ΠΎΠΌ Π²Π°ΡΠΈΠ°Π½ΡΠ΅, Π² ΠΎΡΠ»ΠΈΡΠΈΠ΅ ΠΎΡ Π°ΡΠΈΠΏΠΈΡΠ½ΠΎΠ³ΠΎ, ΡΠ³Π½Π΅ΡΠ΅Π½ΠΈΠ΅ ΡΡΠΈΡΡΠΎΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΈ Π’-Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΠΎΠ³ΠΎ ΡΠΎΡΡΠΊΠΎΠ² Π² ΠΊΠΎΡΡΠ½ΠΎΠΌ ΠΌΠΎΠ·Π³Π΅ Π±ΡΠ»ΠΎ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·Π°Π½ΠΎ Ρ Π²Π΅Π»ΠΈΡΠΈΠ½ΠΎΠΉ Π»Π΅ΠΉΠΊΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠ»Π° Π² ΠΊΡΠΎΠ²ΠΈ.
ΠΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ.
ΠΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½Π° Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΡΡΠΎΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π-Π₯ΠΠ. ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ ΠΌΠ΅ΡΠΎΠ΄ ΠΏΠΎΠ΄ΡΡΡΡΠ° Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ³ΡΠ°ΠΌΠΌ ΠΈ ΠΎΡΡΠ°Π±ΠΎΡΠ°Π½Ρ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΡ ΡΠΈΠΏΠΈΡΠ½ΠΎΠ³ΠΎ ΠΈ ΡΠΌΠ΅ΡΠ°Π½Π½ΠΎ-ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² Ρ Π°ΡΠΈΠΏΠΈΡΠ½ΡΠΌ ΠΈ Π₯ΠΠ/ΠΠ ΠΏΠΎΠ΄Π²Π°ΡΠΈΠ°Π½ΡΠ°ΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ.
Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΠΎΠ³ΠΎ Π°Π½ΡΠΈΠ³Π΅Π½Π° CD38 ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅ΡΡΡ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΡΠ°ΡΠ΅ ΠΏΡΠΈ Π°ΡΠΈΠΏΠΈΡΠ½ΠΎΠΌ Π²Π°ΡΠΈΠ°Π½ΡΠ΅. Π ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΡΠΈ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΌΠΎΠΆΠ΅Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π²Π°ΡΠΈΠ°Π½ΡΠ° Π-Π₯ΠΠ ΠΈ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π°Π½ΡΠΈΠ³Π΅Π½Π° CD38.
Π²ΡΠ²ΠΎΠ΄Ρ.
1. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΡ ΡΠΈΠΏΠΎΠ² Π»Π΅ΠΉΠΊΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ Π² ΠΊΠΎΡΡΠ½ΠΎΠΌ ΠΌΠΎΠ·Π³Π΅ Π±ΠΎΠ»ΡΠ½ΡΡ Π-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ·ΠΎΠΌ (B-XJIJI). ΠΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΠΎΠ΄ΡΡΡΡΠ° Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎ-Π³ΡΠ°ΠΌΠΌ ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° ΠΎΡ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΎΠ²Π°Π½Ρ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π²Π°ΡΠΈΠ°Π½ΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ: ΡΠΈΠΏΠΈΡΠ½ΡΠΉ Π²Π°ΡΠΈΠ°Π½Ρ (53,5% ΡΠ»ΡΡΠ°Π΅Π²) ΠΈ ΡΠΌΠ΅ΡΠ°Π½Π½ΠΎ-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΉ Π²Π°ΡΠΈΠ°Π½Ρ Π-Π₯ΠΠ Ρ Π΄Π²ΡΠΌΡ ΠΏΠΎΠ΄Π²Π°ΡΠΈΠ°Π½ΡΠ°ΠΌΠΈ — Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎ-Π·ΠΎΠΌ/ΠΏΡΠΎΠ»ΠΈΠΌΡΠΎΡΠΈΡΠ°ΡΠ½ΡΠΌ Π»Π΅ΠΉΠΊΠΎΠ·ΠΎΠΌ (Π₯ΠΠ/ΠΠ) (4,5%) ΠΈ Π°ΡΠΈΠΏΠΈΡΠ½ΡΠΌ (42%).
2. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π²Π°ΡΠΈΠ°Π½ΡΡ Π-Π₯ΠΠ ΠΎΡΡΠ°Π²Π°Π»ΠΈΡΡ Π½Π΅ΠΈΠ·ΠΌΠ΅Π½Π½ΡΠΌΠΈ Ρ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° Π±ΠΎΠ»ΡΠ½ΡΡ Π·Π° ΠΏΠ΅ΡΠΈΠΎΠ΄ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΠΎΡ 7 Π΄ΠΎ 47 ΠΌΠ΅ΡΡΡΠ΅Π². Π ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΡ ΡΠ»ΡΡΠ°ΡΡ (13,0%) ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΎΡΡ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π²Π°ΡΠΈΠ°Π½ΡΠ° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΠΏΡΠΈΡΡΠΌ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΠΎ Π½Π°Π±Π»ΡΠ΄Π°Π»ΡΡ ΠΏΠ΅ΡΠ΅Ρ ΠΎΠ΄ ΡΠΈΠΏΠΈΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²Π°ΡΠΈΠ°Π½ΡΠ° Π² Π°ΡΠΈΠΏΠΈΡΠ½ΡΠΉ ΠΏΠΎΠ΄Π²Π°ΡΠΈΠ°Π½Ρ.
3. ΠΠ΅ΠΉΠΊΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ ΠΏΡΠΈ ΡΠ°Π·Π½ΡΡ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π²Π°ΡΠΈΠ°Π½ΡΠ°Ρ Π-Π₯ΠΠ ΠΈΠΌΠ΅Π»ΠΈ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠ°. ΠΡΠΈ Π°ΡΠΈΠΏΠΈΡΠ½ΠΎΠΌ ΠΏΠΎΠ΄Π²Π°ΡΠΈΠ°Π½ΡΠ΅ Π-Π₯ΠΠ. ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΡΠΈΠΏΠΈΡΠ½ΡΠΌ Π²Π°ΡΠΈΠ°Π½ΡΠΎΠΌ ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΎΡΡ Π·Π½Π°ΡΠΈΠΌΠΎΠ΅ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΠΎΠ³ΠΎ Π°Π½ΡΠΈΠ³Π΅Π½Π° CD38 (53,8±3,2 ΠΏΡΠΎΡΠΈΠ² 42,3±3,8, Ρ=0,027). ΠΡΠΈ Π°ΡΠΈΠΏΠΈΡΠ½ΠΎΠΌ ΠΏΠΎΠ΄Π²Π°ΡΠΈΠ°Π½ΡΠ΅ ΡΠΈΡΠ»ΠΎ Π‘038-ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΡΡ ΡΠ»ΡΡΠ°Π΅Π² (37,5%) Π±ΡΠ»ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π²ΡΡΠ΅ (Ρ=0,041) ΡΠ΅ΠΌ ΠΏΡΠΈ ΡΠΈΠΏΠΈΡΠ½ΠΎΠΌ Π-Π₯ΠΠ (21,0%) ΠΈ Π₯ΠΠ/ΠΠ (0,0%). ΠΠ»Ρ Π₯ΠΠ/ΠΠ, ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΎΡΡΠ°Π»ΡΠ½ΡΠΌΠΈ Π²Π°ΡΠΈΠ°Π½ΡΠ°ΠΌΠΈ, Π±ΡΠ»Π° Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠ½Π° Π²ΡΡΠΎΠΊΠ°Ρ ΡΠ°ΡΡΠΎΡΠ° Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠΉ Ρ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ ΠΌΠ°ΡΠΊΠ΅ΡΠ° CD20.
4. ΠΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΊΠΎΡΡΠ½ΠΎΠΌΠΎΠ·Π³ΠΎΠ²ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²Π΅ΡΠ²ΠΎΡΠ΅Π½ΠΈΡ ΠΈ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ Π’-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠ°Π·Π½ΡΠΌΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π²Π°ΡΠΈΠ°Π½ΡΠ°ΠΌΠΈ Π-Π₯ΠΠ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ Π½Π΅ ΡΠ°Π·Π»ΠΈΡΠ°Π»ΠΈΡΡ. Π§Π°ΡΡΠΎΡΠ° Π°Π½Π΅ΠΌΠΈΠΈ, ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠΎΠΏΠ΅Π½ΠΈΠΈ, Π½Π΅ΠΉΡΡΠΎΠΏΠ΅Π½ΠΈΠΈ ΠΈ ΡΠΈΡΠ»ΠΎ ΡΠ»ΡΡΠ°Π΅Π² ΡΡΠ°Π΄ΠΈΠΈ Π‘ ΠΏΠΎ Binet ΡΠ°ΠΊΠΆΠ΅ Π±ΡΠ»ΠΈ Π±Π»ΠΈΠ·ΠΊΠΈ.
5. ΠΡΠΈ ΡΠΈΠΏΠΈΡΠ½ΠΎΠΌ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ Π²Π°ΡΠΈΠ°Π½ΡΠ΅ Π-Π₯ΠΠ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ· Π² ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ ΠΊΠΎΡΡΠ΅Π»ΠΈΡΠΎΠ²Π°Π» Ρ ΡΠ°ΡΡΠΎΡΠΎΠΉ Π°Π½Π΅ΠΌΠΈΠΈ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½Π°Ρ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΡ Π²Π΅Π»ΠΈΡΠΈΠ½Ρ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ·Π° ΡΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° ΡΡΠΈΡΡΠΎΡΠΈΡΠΎΠ² (Ρ=0,004), ΡΡΠΎΠ²Π½Ρ Π³Π΅ΠΌΠΎΠ³Π»ΠΎΠ±ΠΈΠ½Π° (Ρ=0,003), ΠΏΡΠΎΡΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ Π½Π΅ΠΉΡΡΠΎΡΠΈΠ»ΠΎΠ² (Ρ=0,0001). ΠΠΎΠΊΠ°Π·Π°Π½Π° ΠΏΡΡΠΌΠ°Ρ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·Ρ ΡΠΈΡΠ»Π° Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ Π² ΠΊΡΠΎΠ²ΠΈ ΠΈ ΠΊΠΎΡΡΠ½ΠΎΠΌ ΠΌΠΎΠ·Π³Π΅. ΠΡΡΠ²Π»Π΅Π½Π° Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½Π°Ρ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡ ΠΌΠ΅ΠΆΠ΄Ρ Π²Π΅Π»ΠΈΡΠΈΠ½ΠΎΠΉ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ·Π° Π² ΠΊΡΠΎΠ²ΠΈ ΠΈ ΡΡΠ΅ΠΏΠ΅Π½ΡΡ ΡΠ³Π½Π΅ΡΠ΅Π½ΠΈΡ Π’-Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΠΎΠ³ΠΎ ΡΠΎΡΡΠΊΠ° Π² ΠΊΠΎΡΡΠ½ΠΎΠΌ ΠΌΠΎΠ·Π³Π΅.
6. ΠΡΠΈ Π°ΡΠΈΠΏΠΈΡΠ½ΠΎΠΌ ΠΏΠΎΠ΄Π²Π°ΡΠΈΠ°Π½ΡΠ΅ Π½Π΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»Π°ΡΡ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡ ΠΌΠ΅ΠΆΠ΄Ρ Π²Π΅Π»ΠΈΡΠΈΠ½ΠΎΠΉ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ·Π° Π² ΠΊΡΠΎΠ²ΠΈ ΠΈ ΡΠ°ΡΡΠΎΡΠΎΠΉ Π°Π½Π΅ΠΌΠΈΠΈ. Π§ΠΈΡΠ»ΠΎ Π»Π΅ΠΉΠΊΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΊΡΠΎΠ²ΠΈ ΠΊΠΎΡΡΠ΅Π»ΠΈΡΠΎΠ²Π°Π»ΠΎ Ρ ΠΈΡ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ΠΌ Π² ΠΊΠΎΡΡΠ½ΠΎΠΌ ΠΌΠΎΠ·Π³Π΅. ΠΡΡΡΡΡΡΠ²ΠΎΠ²Π°Π»Π° ΡΠ²ΡΠ·Ρ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ·Π° ΠΊΡΠΎΠ²ΠΈ Ρ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²ΠΎΠΌ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Π’-Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΠΎΠ³ΠΎ ΡΡΠ΄Π°.
7. Π Π°Π·Π»ΠΈΡΠΈΡ Π² ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΠ³Π½Π΅ΡΠ΅Π½ΠΈΡ ΠΊΡΠΎΠ²Π΅ΡΠ²ΠΎΡΠ΅Π½ΠΈΡ (ΡΡΠΈΡΡΠΎΠΈΠ΄Π½ΠΎΠ³ΠΎ ΡΠΎΡΡΠΊΠ° ΠΈ Π’-Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΠΎΠ³ΠΎ ΡΡΠ΄Π°) ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡ ΠΎ ΡΠ°Π·Π½ΡΡ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΡ Π»Π΅ΠΉΠΊΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΏΡΠΈ ΡΠΈΠΏΠΈΡΠ½ΠΎΠΌ Π²Π°ΡΠΈΠ°Π½ΡΠ΅ ΠΈ Π°ΡΠΈΠΏΠΈΡΠ½ΠΎΠΌ ΠΏΠΎΠ΄Π²Π°ΡΠΈΠ°Π½ΡΠ΅ Π-Π₯ΠΠ.
8. Π ΡΠ°Π·Π½ΡΡ Π²ΠΎΠ·ΡΠ°ΡΡΠ½ΡΡ Π³ΡΡΠΏΠΏΠ°Ρ (I — <50 Π»Π΅Ρ, II — ΠΎΡ 51 Π΄ΠΎ 69 Π»Π΅Ρ ΠΈ III — 70 Π»Π΅Ρ ΠΈ ΡΡΠ°ΡΡΠ΅) ΡΠ°ΡΡΠΎΡΠ° ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² Π-Π₯ΠΠ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ Π½Π΅ ΡΠ°Π·Π»ΠΈΡΠ°Π»Π°ΡΡ. Π‘ΡΠ΅ΠΏΠ΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΠΎΠ³ΠΎ Π°Π½ΡΠΈΠ³Π΅Π½Π° CD38 ΠΈ ΡΠΈΡΠ»ΠΎ Π‘Π38-ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΡΡ ΡΠ»ΡΡΠ°Π΅Π² Π±ΡΠ»ΠΈ ΠΎΠ΄ΠΈΠ½Π°ΠΊΠΎΠ²Ρ ΡΡΠ΅Π΄ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΠ°Π·Π½ΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ°. Π‘ΠΎΡΡΠΎΡΠ½ΠΈΠ΅ Π³Π΅ΠΌΠΎΠΏΠΎΡΠ·Π° Π½Π΅ ΠΈΠΌΠ΅Π»ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΡ ΡΠ°Π·Π»ΠΈΡΠΈΠΉ Π² ΡΠ°Π·Π½ΡΡ Π²ΠΎΠ·ΡΠ°ΡΡΠ½ΡΡ Π³ΡΡΠΏΠΏΠ°Ρ Π±ΠΎΠ»ΡΠ½ΡΡ .
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠ΅ΡΡΠΌΠ΅Π»ΡΡΠ΅Π² Π‘.Π‘., ΠΡΠ»ΠΈΠΊ Π’. Π., ΠΠΎΠ»ΠΊΠΎΠ²Π° Π. Π. ΠΈ Π΄Ρ. Π Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΠΏΠΎ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ Π-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ·ΠΎΠΌ // Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½Π°Ρ ΠΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡ. 2008. — Ρ. 10. — Π‘. 10−15.
- ΠΡΠ»ΠΈΠΊ Π’.Π. ΠΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ°ΡΠΊΠ΅ΡΡ ΠΊΠ°ΠΊ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ°ΠΊΡΠΎΡΡ ΠΏΡΠΈ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ·Π΅. ΠΠΈΡ. ΠΊΠ°Π½Π΄. ΠΌΠ΅Π΄. Π½Π°ΡΠΊ. Π., 2004. — 185 Ρ.
- ΠΠΎΠ»ΠΊΠΎΠ²Π° Π.Π. Π₯ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ· // ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΠ½ΠΊΠΎΠ³Π΅ΠΌΠ°ΡΠΎ-Π»ΠΎΠ³ΠΈΡ / ΠΠΎΠ΄ ΡΠ΅Π΄. ΠΏΡΠΎΡ. Π. Π. ΠΠΎΠ»ΠΊΠΎΠ²ΠΎΠΉ. Π.: ΠΠ΅Π΄ΠΈΡΠΈΠ½Π°, 2007. — Π‘. 771−807.
- ΠΠΎΡΠΎΠ±ΡΠ΅Π² Π.Π., ΠΡΠΈΠ»Π»ΠΈΠ°Π½Ρ Π. Π., ΠΡΠ΅ΠΌΠ΅Π½Π΅ΡΠΊΠ°Ρ A.M. ΠΈ Π΄Ρ. Π₯ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ· ΠΈ Π»ΠΈΠΌΡΠΎΠΌΠ° ΠΈΠ· ΠΌΠ°Π»ΡΡ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² // Π ΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ²ΠΎ ΠΏΠΎ Π³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ: Π 3 Ρ. / ΠΠΎΠ΄ ΡΠ΅Π΄. Π°ΠΊΠ°Π΄. ATI. ΠΠΎΡΠΎΠ±ΡΠ΅Π²Π°. Π.: ΠΡΡΠ΄ΠΈΠ°ΠΌΠ΅Π΄, 2003. — Π’. 2 — Π‘. 69−82.
- ΠΠΎΡΠΎΠ±ΡΠ΅Π² Π.Π., ΠΡΠ΅ΠΌΠ΅Π½Π΅ΡΠΊΠ°Ρ A.M. Π₯ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ Π-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΉ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ· // ΠΡΠ»Π°Ρ ΠΎΠΏΡΡ ΠΎΠ»ΠΈ Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ / ΠΠΎΠ΄ ΡΠ΅Π΄. Π°ΠΊΠ°Π΄. Π. Π. ΠΠΎΡΠΎΠ±ΡΠ΅Π²Π°. ΠΈ ΠΏΡΠΎΡ. Π. Π. ΠΡΠ΅ΠΌΠ΅Π½Π΅ΡΠΊΠΎΠΉ Π.: ΠΡΡΠ΄ΠΈΠ°ΠΌΠ΅Π΄, 2007. — Π’. 1. — Π‘. 72−91.
- ΠΡΠΈΠ±ΠΎΠ²Π° Π.Π., ΠΠΎΡΠΎΠ±ΡΠ΅Π² Π. Π. ΠΠ΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ Π½ΠΎΡΠΌΠ°. // Π ΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ²ΠΎ ΠΏΠΎ Π³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ: Π 3 Ρ. / ΠΠΎΠ΄ ΡΠ΅Π΄. Π°ΠΊΠ°Π΄. Π. Π. ΠΠΎΡΠΎΠ±ΡΠ΅Π²Π°. Π.: ΠΡΡΠ΄ΠΈΠ°ΠΌΠ΅Π΄, 2002. -Π’. 1.-Π‘. 61−63.
- ΠΡΠ³ΠΎΠ²ΡΠΊΠ°Ρ Π‘.Π., ΠΠΎΡΡΠ°ΡΡ Π. Π., Π’ΡΠΏΠΈΡΡΠ½ Π. Π. ΠΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π² Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ Π³Π΅ΠΌΠΎΠ±Π»Π°ΡΡΠΎΠ·ΠΎΠ². Π.: ΠΠ°ΡΠ΅Π΄ΡΠ° ΠΠΠ, 2005. — Π‘.55−165.
- ΠΡΠΌΠ°Π½ΠΎΠ² Π.Π¨., Π’ΡΠΏΠΈΡΡΠ½ Π. Π., ΠΠΎΠ½Π΄ΡΠ°ΡΡΠ΅Π²Π° Π’.Π’.- Π‘ΠΈΠ½Π΄ΡΠΎΠΌ Π ΠΈΡ ΡΠ΅ΡΠ° // ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΠ½ΠΊΠΎΠ³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡ. / ΠΠΎΠ΄ ΡΠ΅Π΄. ΠΏΡΠΎΡ. Π. Π. ΠΠΎΠ»ΠΊΠΎΠ²ΠΎΠΉ. Π.: ΠΠ΅Π΄ΠΈΡΠΈΠ½Π°, 2007. — Π‘. 813−818.
- Π Π°Π±ΡΠΎΠ½ Π., Π ΠΎΠΉΡ Π., ΠΠ΅Π»Π²Π· Π. ΠΡΠ½ΠΎΠ²Ρ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΠΈ: ΠΠ΅Ρ. Ρ Π°Π½Π³Π». Π.: ΠΠΈΡ, 2006. — Π‘.26−39.
- Π’ΡΠΏΠΈΡΡΠ½ Π.Π. ΠΠΌΠΌΡΠ½ΠΎΠ΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° Π³Π΅ΠΌΠΎΠ±Π»Π°ΡΡΠΎΠ·ΠΎΠ² // ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΠ½ΠΊΠΎΠ³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡ. / ΠΠΎΠ΄ ΡΠ΅Π΄. ΠΏΡΠΎΡ. Π. Π. ΠΠΎΠ»ΠΊΠΎΠ²ΠΎΠΉ. Π.: ΠΠ΅Π΄ΠΈΡΠΈΠ½Π°, 2001. — Π‘. 124−145.
- Π’ΡΠΏΠΈΡΡΠ½ Π.Π. ΠΠΈΠΌΡΠΎΡΠΈΡΡ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠΊΠΎΠΌΠΏΠ΅ΡΠ΅Π½ΡΠ½Π°Ρ ΡΠΈΡΡΠ΅ΠΌΠ° // Π ΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ²ΠΎ ΠΏΠΎ Π³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ: Π 3 Ρ. / ΠΠΎΠ΄ ΡΠ΅Π΄. Π°ΠΊΠ°Π΄. Π. Π. ΠΠΎΡΠΎΠ±ΡΡΠ²Π°. Π.: ΠΡΡΠ΄ΠΈΠ°ΠΌΠ΅Π΄, 2002. — Π’.2. — Π‘. 106−129.
- Π§ΠΈΡΡΠΎΠ² Π.Π., Π‘ΡΠ°ΡΠΈΠ½ΡΠΊΠΈΠΉ Π. Π., ΠΠ΅ΡΡΠΎΠ²Π° Π. Π. ΠΠ»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ Π² Π ΠΎΡΡΠΈΠΈ Π² 2007 Π³ΠΎΠ΄Ρ (Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΡ ΠΈ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΡ). Π., 2009. — Π‘.42.
- Apostopoulos A., Symeonidis A., Joumbos P. Prognostic significance of immune function parameters in patients with chronic lymphocytic leukemia. Eur J Haematology 1990, vol. 44, pp. 39−44.
- Aubry J.P., Pochon S., Graber P., Jansen K.U., Bonnefoy J.Y. CD21 is a ligand for CD23 and regulates Ig E production. Nature 1992, vol. 358, pp. 505−507.
- Bagli L., Zucchini A., Innoceta A.-M. Immunoglobulin VH Genes and CD38 Expression Analysis in B-Cell Chronic Lymphocytic Leukemia. Acta Haematologica 2006, vol. 116, pp. 72−74.
- Ballrich F., Rasio D., Kitada S. et al. ATM mutations in B-Cell Chronic Lymphocytic Leukemia. Cancer Research 1999, vol. 59, pp. 24−27.
- Bama G., Reininger L., Tatrai P. et al. The cut-off levels of CD23 expression in the differential diagnosis of MCL and CLL. Hematology Oncology 2008, vol. 26(3), pp. 167−170.
- Beaume A., Brizard A., Dreyfus B. and Preud’homme J.L. High incindence of serum monoclonal IgS detected by sensitive immunobloting techniqve in B-CLL. Blood 1994, vol. 84, pp. 1216−1219.
- Bennett J.M., Rafael Π., Oken M.M. et al. The prognosis of chronic lymphocytic leukemia under age 50 years. Nouv Rev Fr Hematol 1988, vol. 30, pp. 411— 412.
- Bennet J.M., Catovsky D., Daniel M.T. et al. Proposals for the classification of chronic (mature) Π and T lymphoid leukemias. French-American-British (FAB) Cooperative Group. J Clin Patol 1989, vol. 42, pp. 567−584.
- Benoist Π., McLean E., Egli I. Worldwide prevalence of anemia 19 932 005. WHO Global Database on Anaemia. WHO Geneva 2008, p. 4.
- Bergui L., Tesio L., Schena M. et al. CDS and CD21 molecules are functional unit in the cell/ substrate adhezion of B-chronic lymphocytic leukemia cells. European Journal of Immunology 2005, vol.18, pp. 89−96.
- Bigoni R., Cuneo A., Roberti M.G. et al. Chromosome abberation in atypical chronic lymphocytic leukemia: a cytogenetic and interphase cytogenetic study. Leukemia 1997, vol. 11, pp. 1933−1940.
- Binet J.L., Auquier A., Dighiero G. et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981, vol. 48, pp. 198−206.
- Bodey G.P., Kontoyiannis D., Keating M.J. Infections in Patients With Chronic Lymphocytic Leukemia. In: Chronic Lymphocytic Leukemia. Ed. by Guy B. Fagvet. Humana Press Inc., Totowa., New Jersey, 2004, pp. 343−360.
- Boggs D.R., Chen S.C., Zhang Z.N. et al. Chronic lymphocytic leukemia in China. Am J Hematol 1987, vol. 95, pp. 349−354.
- Boice J.D., Lahd C.E., Preston D.L. Ionizin radiation. In: Schottenfeld D., Fraumen J.F. eds. Cancer Epidemiology and Prevention, NY: Oxford University Press 1996, pp. 319−354.
- Boonstra J.G., van Lom K., Langerak A.W. et al. CD38 as a prognostic factor in Π cell chronic lymphocytic leukemia (B CLL): comparison of three approaches to analyze its expression. Cytometry. Part B, Clinical Cytometry 2006, vol. 70(3), pp. 136−141.
- Bosch F., Montserrat E. Prognostic Indicators of Chronic Lymphocytic Leukemia. In: Chronic Lymphocytic Leukemia. Ed. by Guy B. Fagvet. Humana Press Inc., Totowa., New Jersey, 2004, pp. 201−218.
- Blair A., Purdue M.P., Weisenburgen D.P., Baris D. Chemical exposures and risk of chronic lymphocytic leukemia. Br J Haematology 2007, vol.139, pp. 753 761.
- Brugiatelli M., Jaksic Π., Planic-Peraica A. et al. Treatment of chronic lymphocytic leukemia in early and stable phase of the disease: Long term results of a randomized trial. Eur J Haematol 1995, vol. 55, pp. 158−163.
- Bund D., Mayr C., Kofler D. et al. CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologus T lymphocytes. Exp Hematol 2007, vol. 35(6), pp. 920−930.
- Call T.G., Phyliky R.L., Noel P. et al. Incindence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc 1994, vol. 69(4), pp. 323−328.
- Calligaris-Cappio F., Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 2008, vol. 26, pp. 4497−4503.
- Cartwright R.A. Summary of epidemiology and immunobiology. In: Laboratory Approaches, USPHS Atlanta 1997, pp. 215−222.
- Catovsky D., Fooks J., Richards S. et al. The UK Medical Research Council CLL trials 1 and 2. Nouv Rev Fr Hematol 1988, vol. 30, pp. 423−427.
- Chen L., Widhopf G., Huynh L. et al. Expression of Zap 70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002, vol.100, pp. 4609−4614.
- Cheson B.D., Bennett J.M., Grever M. et al. National Cancer Institute sponsored working group guirdelines for chronic lymphocytic leukemia: revised guirdelinesfor diagnosis and treatment. Blood 1996, vol. 87, pp. 4990−4997.
- Chevalier P., Penther D., Avet-Loiseau H. et al. CD38 expression andsecondary 17p deletion are important prognostic factors in chronic lymphocytic leukemia. Br. J. Haematol 2002, vol. 116, pp. 142−150.
- Chiorazzi N, Ferrarini M. Π Cell Chronic Lymphocytic Leukemia: lessons learned from studies of the Π cell antigen receptor. Annu Rev Immunol 2003, vol. 21, pp. 841−894.
- Gochard N., Salviat A., Catheine B. et al. Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using anoptmised flow cytometry method. Hematologica 2008, vol. 93(2), pp. 215−223.
- Crespo M., Bosch F., Villamor N. et al. ZAP-70 expression as a surrogate for immunoglobulin variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, vol. 348, pp. 1764−1775.
- Criel A., Wlodarska I., Meus P. et al. Trisomy 12 is uncommon in typical chronic lymphocytic leukemias. Br J Haematol 1994, vol. 87, pp. 523−528.
- Criel A., Verhofer G., Vlietinck R. et al. Futher characterization of morfologically defined typicaly and atypical CLL: a clinical, immunophenotypic, cytogenetic and prognostic study on 390 cases. Br. J. Haematol 1997, vol. 97(2), pp. 383−391.
- Cro L., Morabito F., Zulcal N. et al. CD26 expression in mature B-cell neoplasia: its possible role as a new prognos marcer in B-CLL. Hematological Oncology 2009, vol. 27(3), pp. 140−147.
- Crowther-Swanepoel D., Houlston R.S. The molecular basis of familial chronic lymphocytic leukemia. Haematologica 2009, vol. 94, pp. 606−609.
- Cruse J.M., Lewis R.E., Webb R.N. ZAP70 and CD38 as predictors of IgVFI mutation in CLL. Experimental and Molecular Pathology 2007, vol. 83, pp. 459−461.
- Cutrona G., Colombo M., Matis S. et al. Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surfase lg M cross-linking in CD38, ZAP-70-positive cells. Haematologica 2008, vol. 93(3), pp. 413−422.
- Dadmarz Z.R., Cawley J.C. Heterogeneity of CLL: high CD23 antigen andalpha IFN receptor expression are features of favourable disease and of cell activation. Br J Haematol 1998, vol. 69(3), pp. 279−282.
- Damle R.N., Wasil Π’., Fais F. et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, vol. 94(6), pp. 1840−1847.
- D"Arena G., Musto P., Cascavilla N. et al. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol 2000, vol. 64, pp. 275−281.
- D"Arena G., Dell Olio M., Musto P. et al. Morphological typical and atypical B-cell chronic lymphocytic leukemias display a different pattern of surfase antigenic density. Leuk Lymphoma 2001, vol. 42, pp. 649−654.
- Deaglio S., Capobianca A., Bergui L. et al. CD38 is signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003, vol. 102(6), pp. 2146−2155.
- Deaglio S., Malavasi F. Chronic lymphocytic leukemia a microenvivon-ment: shiffting the balance from apoptosis to proliferation/ Haematologica 2009, vol. 94, pp. 752−756.
- Del Giudice D., Mauro F.R., De Propis M. et al. A prospective Study of Young Chronic Lymphocytic Leukemia (CLL) Patients Investigated at Diagnosis: Distribution and Clinical Significance of Prognostic Factors. Blood, vol. 12, abstr. 3121.
- De Lima M., O’Brien S., Lemer S. et al. Chronic lymphocytic leukemia in the yonger patient. Semin Oncol 1998, vol. 25, pp. 107−116.
- Deneys V., Michaux L., Leveugle P. et al. Atypical lymphocytic leukemia and mantle cell lymphoma immunologicaly very close: Flow cytometric distinction by use of CD 20 and CD 54 expression. Leukemia 2001, vol. 15, pp. 1458−1465.
- Desablens Π., Garidi R., Fernances J., et al. Serum LDG and (Π-^-Ρ in B
- CLL: analysis on 315 patients. Leukemia 2000, Program and abstract book, p. 62, abstr. p. 069.
- Dohner H., Stilgenbauer S., James M.R. et al. 1 lq deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997, vol. 89, pp. 2516−2522.
- Duek A., Shvidel L., Braesler A. et al. Clinical and Immunological Aspects of B-CLL. Associated with Autoimmune Disorders. Hematology 2006, vol. 8, pp. 828−831.
- Duhrsen U., Augener W., Zwingers Π’., et al. Spectrum and frequency of autoimmune erangerments in lymphoproliferative disorders: analysis of 637 cases and comparison with mieloproliferative disease. Br J Haematol 1987, vol. 67, pp. 235−239.
- Durig J., Nashan M., Schmulcer U. Et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukemia. Leukemia 2002, vol. 16, pp. 3035.
- Eriksson M., Hardell L., Carlberg H. and Akerman M. Pesticide exposure as risk factor for non-Hodgkin lymphoma including histopathological subgroup analysis. Int J Cancer 2008, vol. 123, pp. 1657−1663.
- Foa R., Catovsky D., Brozovic M. et al. Clinical staging and immunological findings in chronic lymphocytic leukemia. Cancer 1979, vol. 44, pp. 483−487.
- Frater J.L., McCarron K.F., Hammel G.P. et al. Typical and Atypical Chronic Lymphocytic Leukemia Differ Clinically and Immunophenotypically. Am J Clin Pathol 2001, vol. 116(5), pp. 665−664.
- Gagroa A., Dasic G., Sabiooncello A. et al. Phenotypic analysis of recep-tor-ligand pains on B-Cells in B-chronic lymphocytic leukemia. Leuk Lymphoma 1997, vol. 25(3−4), pp. 301−311.
- Galton D.A.G. The natural history of chronic lymphocytic leukemia. M.D. thezis Cambridge University, Cambridge, 1963.
- Galton D.A.G. The pathogenezis of chronic lymphocytic leukemia. Can Med Assoc J 1966, vol. 94, pp. 1005−1010.
- Gary-Gouy H., Ilarriagve J., Bismuth G. et al. Human CD5 promotes Π cell survival through stimulation of autocrine IL10 production. Blood 2002, vol. 100(13), pp.4537−4543.
- Geisler C.H., Hansen M. Chronic lymphocytic leukemia: a test of a new proposed staging system. Scand J Haematol 1981, vol. 27, pp. 279−286.
- Geisler C.H., Larsen J.K., Hansen N.E. et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood 1991, vol. 78, pp. 1795−1802.
- Goldin L.R., Sgambati M., Marty G.E. et al. Anticipation in familial chronic lymphocytic leukemia. Am J Hum Genet 1999, vol. 65, pp. 265−269.
- Goldin L.R., Pfeiffer R.M., Li X. et al. Familial risk of lymphoprolifertive tumors in families of patients with chronic lymphocytic leukemia: results from Swedish Family Cancer Database. Blood 2004, vol. 104, pp. 1850−1854.
- Goldin L.R., Bjokholm M., Kristiusson S.Y.et al. Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica 2009, vol. 4, pp. 647 653.
- Hamblin T.J., Davis Z., Gardiner A. et al. Unmutated IgVh gene are associated a more aggressive from of chronic lymphocytic leukemia. Blood 1999, vol. 94(6), pp. 1848−1854.
- Hamblin T.J. CD38: what is there fo? Blood 2003, vol. 102(6), pp. 19 391 940.
- Hamblin T.J. Aggressive transformation and paraneoplastic complication of CLL. In: Clinical malignant hematology. By ed. Rusko J., Pancotti R., Brown R.Y., USA 2007, pp. 251−264.
- Hernandez J.M., Mecucci C., Criel A. et al. Cytogenetic analysis of Π cell chronic lymphocytic leukemias classified according to morphologic and immunophe-notypic (FAB) criteria. Leukemia 1995, vol. 9(12), pp. 2140−2146.
- Herrmann F., Lochner A., Phillippen H. et al. Imbalance of T-cell subpopu-lations in patients with chronic lymphocytic leukemia of B-cell type. Clin Exp Immunol 1982, vol. 49(1), pp. 157−162.
- Higs I., Kay N.E., Ranhein E. et al. Malignant Π cell CD5 membrane phe-notype and Π cell colony growth in vivo and in vivo in patients with B-chronic lymphocytic leukemia: analysis with clinical parameters. Leuk Lymphoma 1993, vol. 12(1−2), pp. 59−67.
- Hiller E. Bleeding Disorders. In: Modern Hematology Second Edition. Ed by Munker R. Totowa, New Jersey, Humana Press 2007, p. 350.
- Hoffkes H.-G., Schmidtke G., Uppenkamp M., et al. Multiparametric Im-munophenotyping of Π Cells in Peripheral Bllod of Healthy Adults by Flow Cytometry. Clinical and Diagnostic Laboratory Immunology 1996, vol. 3(1), pp. 30−36.
- Hogan W.F., Tefferi A., Borrell T.J. et al. Prognostic relevance of monosomy at the 13ql4 locus detected by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 1999, vol. 110, pp. 77−81.
- Horwitz M., Goode E.L., Jarvik G.P. Anticipation in familial chronic lymphocytic leukemia. Am J Hum Genet 1996, vol. 59, pp. 990−998.
- Hsi E.D., Kopecky K.J., Appelbaum F.R. et al. Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukemia. Br J Flaematol 2003, vol. 120(60), pp. 1017−1025.
- Huh Y.O., Pugh W.C., Kantrjian H.M. et al. Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody. Am J Clin Pathol 1994, vol. 101(3), pp. 283−289.
- Hus I., Podhoreska M., Bojarska K.A. et al. The clinical significanse of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukemia. Ann Oncol 2006, vol. 17, pp. 683−690.
- Ibrahim S., Keating M., Do K.A. et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001, vol. 98, pp. 181−186.
- Ingle G.S., Chan P., Elliot G. et al. High CD21-expression inhibits internalization of anti-CD 19-antibodies and cytotoxicity of an anti-CD 19-drag conjugate. Br J Haematol 2008, vol. 140(1), pp. 46−58.
- Jaksic Π., Vrhovac R., Kusec R. et al. Clinical tumor cell distribution pattern is a prognostically relevant parameter in patients with B-cell chronic lymphocytic leukemia. Haematologica 2001, vol. 86, pp. 827−836.
- Jefferson D., Upshow J., Cullihan T.R. et al. Spontaneous remission on B-cell chronic lymphocytic leukemia associated with T lymphocytic hyperplasia in bone marrow. Southern Medical Journal 2002, June, online.
- Jemal A., Murray Π’., Samuels A. et al. Cancer statistics 2003, CA Cancer J Clin 2003, vol. 53, pp. 5−26.
- Jurisic V., Colovic M., Colovic N, Kraguliac N. Analysis of percentage CD23 cell membrane molecule expressed in ratio to the immunoglobulines concentration in in B-CLL. Eur J Cancer 2003, suppl, vol. 1(5), pS 305.
- Katrinakis G., Kyriakou D., Alexanddrakis M. et al. Evidence for involvement of activated CD8+/ HLA- DR+ cells in the pathogenesis of neutropenia in patients with B-cell chronic lymphocytic leukemia. Eur J Haematol 1995, vol. 55, pp. 33−41.
- Klein U., Th Y., Stolovitzky G. A. et al. Gene expression profiling of Π chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory Π cells. J Exp Med 2001, vol. 194(11), pp. 1625−1638.
- Kozuch P., O’Brien S., Kantarjian H. et al. The M.P. Anderson Cancer Center Experience in CLL patients aged 70 years and older. In: VHIth International Workshop on CLL, Paris, Programme and Abstract Book, 1999, p. 61.
- Landgren O., Engels E.A., Caporaso N.E. et al. Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries. Blood 2006, vol. 108, pp. 292−296.
- Landgren O., Rapkin J.S., Caporaso N.E. Respiratory tract infections andsubsequent risk of chronic lymphocytic leukemia. Blood 2007, vol. 109, pp. 21 982 201.
- Lavabre-Bertrand Π’., Exbrayat C., Bourguard P. et al. CD23 antigen density is related to serumgammaglobulin level, bone marrow reticulin pattern, and treatment in Π chronic lymphocytic leukemia. Leukemia Lymphoma 1994, vol. 13(1−2), pp. 89−94.
- Leavell B.S. Chronic leukemia: a study of incindence and factors influencing the duration of life. Am J Med Sci 1938, vol. 196, pp. 329−340.
- Lee J.S., Dixon D.O., Kantarjian H.P. et al. Prognosis of chronic lymphocytic leukemia: Multivariate regression analysis of 325 untreated patients. Blood 1987, vol. 5, pp. 398−406.
- Lewintre E.J., Martin C.R., Ballesteros C.G. et al. Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia. Haema-tologica 2009, vol. 94(2), pp. 280−284.
- Lopez-Matas M., Rodriguez-Justo M., Morilla M. et al. Quantitative expression of CD23 and its ligand CD21 in chronic lymphocytic leukemia. Haema-tologica 2000, vol. 85, pp. 1140−1145.
- Malavasi F., Deaglio S., Funaro A. et al. Evolution and function of the ADD ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rew 2008, vol. 88, pp. 841−886.
- Mandelli F., De Rossi G., Mancini P. et al. Prognosis in chronic lymphocytic leukemia: A retrospective multicentric study from the GINEMA Group. J Clin Oncol 1987, vol. 5, pp. 398−406.
- Matutes E., Owusu-Aukomah K., Morilla R. et al. The immunologicalprofile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994, vol. 8, pp. 1640−1645.
- Matutes E., Oscier D., Garcia-Marco J. et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 1996, vol. 92, pp. 382−388.
- Matutes E., Halsey J., Morilla R. et al. Prognostic significance of membrane antigens and morphology in chronic lymphocytic leukemia. Blood 1999, vol. 94, pp. 535.
- Matutes E., Polliack A. Morphological and Immunophenotypic features of Chronic Lymphocytic Leukemia. Reviews in Clinical and Experimental Hematology 2000, vol. 4(1), pp. 22−47.
- Marti G.E., Faguet G.B., Stewart C. et al. Evolution of leukemic hetero-genity of human B-CLL lymphocytes between and within patients. Current Topics in Microbiology and Immunology 1992, vol. 182, pp. 303−311.
- Marti G.E., Carter D., Abbasi F. et al. B-cell monoclonal lymphocytosis and B-cell abnormalites in the setting of familial B-cell chronic lymphocytic leukemia. Cytometry 2003, vol. 52, pp. 1−12.
- Marti G.E., Zenger V. The natural History of CLL: Historical Perspective. In: Chronic Lymphocytic Leukemia. Ed. by Guy B. Fagvet. Humana Press Inc., To-towa., New Jersey, 2004, pp. 3−56.
- Martin A.D., Martin E.R., Garsia-Suarez J. et al. A low blood lymphocyte count is associated with an expansion of activated cytotoxic lymphocytesin patients with B-cell chronic lymphocytic leukemia. Eur J Hematol 1997, vol. 59, pp. 89−99.
- Mauro F.R., Foa R. Young Patients with Chronic Lymphocytic Leukemia.1.: Chronic Lymphocytic Leukemia Ed. by Guy B. Fagvet. Humana Press Inc., To-towa., New Jersey, 2004, pp. 401−413.
- Mauro F.R., Giamartini E., Gentile M. et al. Clinical features and outcome of familial chronic lymphocytic leukemia. Haematologica 2006, vol. 94, pp. 11 171 120.
- Mayr C., Speicher M.R., Kofler D.M. et al. Chromosomal translocation are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006, vol. 107, No. 2, pp. 742−751.
- Melo J.V., Catovsky D., Galton D.A. The relationship between chronic lymphocytic leukemia and prolymphocytoid transformation. Br J Haematol 1986, vol. 64, pp. 77−86.
- Merino A., Rozman M., Esteve J. et al. Chronic (B-cell) lymphocytic leukemia with unusual granulation. Br J Haematol 2006, vol. 133(4), p. 354.
- Molica S., Brugiatelly M., Callea V. et al. Comparision of younger versus older B-cell chronic lymphocytic leukemia patients for clinical presentation and prognosis. A retrospective study of 53 cases. Eur J Haematol 1994, vol. 52(4), pp. 216−221.
- Montserrat E., Gomis F., Vallespi T. et al. Presenting Features and Prognosis of Chronic Lymphocytic Leukemia in Younger Adults. Blood 1991, vol. 78, pp. 1545−1551.
- Morton L.M., Wang S.S., Devesa S.S. et al. Lymphoma incindence patterns by WHO subtype in the United States 1992−2001. Blood 2006, vol.107, pp. 265−276.
- Munker R. Leukocytosis, Leukopenia, and Other Reactive Changes of Myelopoesis. In: Modern Hematology Second Edition. Ed by Munker R. Totowa, New Jersey, Humana Press 2007, p. 127.
- Nissen M.N. Proteolic modification of (32 -microglobulin in human serum.
- Danish Medical Bulletin 1993, vol. 40, No. 1, pp. 56−61.
- Nuckel H., Huttman A., Klein-Hitpass L. et al. Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2006, vol. 47 (6), pp. 1053−1061.
- Oppezzo P., Vasconcelos Y., Settegrana C. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005, vol. 106(2), pp. 650−657.
- Oscier D. Cytogenetic and molecular abnormalites in chronic lymphocytic leukemia. Blood Rev 1994, vol. 8, pp. 88−97.
- Ottagio L., Viaggi S., Zunino A. et al. Chromosome abberations evaluated by comparative genomic hybridization in B-cell chronic lymphocytic leukemia: correlation with CD38 expression. Haematologica 2003, vol. 88, pp. 769−777.
- Paneesha S., Milligan D.W. Stem cell transplantation for chronic lymphocytic leukemia. Br J Haematol 2005, vol. 128, pp. 145−152.
- Pangalis G.A., Reverten J.C., Boussiotis V.A. et al. Chronic lymphocytic leukemia in yonger adults: preliminary results of study based on 454 patients IWCLL Working Group. Leuk Lymphoma 1991, vol. 5, pp. 175−181.
- Papajik Π’., Knotkova R., Jarosova M. et al. Implication of new factors in the routine asseasment of prognosis in chronic lymphocytic leukemia patients. Leuk Lymphoma 2001, vol. 42, suppl. 1, p. 17, abstr. 2.
- Parkes H.C., Veys C.A., Waterhouse J.A., Peters A. Cancer mortality in the British rubber industry. Br J Ind Med 1982, vol. 39, pp. 209−220.
- Pepper C., Lin T.T., Pratt G. et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukaemia and is associated with other poor prognostic markers. Blood 2008, vol. 112, pp. 3807−3817.
- Pescovich M. Rituximab an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action. Journal of transplantation 2006, vol. 6(5), pp. 859−866.
- Pileri S.A. and Falini B. Mantle cell lymphoma. Haematologica 2009, vol. 94(11), pp. 1488−1492.
- Qve Π’.Π., Garsia-Marco J., Ellis J. et al. Trisomy 12 in Chronic lymphocytic leukemia detected by fluorescence in situ hybridization: analysis by stage, im-munophenotype and morphology. Blood 1993, vol. 82, pp. 571−575.
- Raabe G.K., Wong O. Leukemia mortality by cell type in petroleum workers with potential exposure to benzene. Environ Health Perspect 1996, vol. 104 (suppl 6), pp. 1381−1392.
- Rachel J.M., Zucker M.L., Plapp F.L. et al. Π cell monoclonal lymphocytosis in blood donors. Blood 2002, vol. 100, 590 a abstract.
- Rai K.R., Sawitsky A., Cronckite E.P. et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975, vol. 46, pp. 219−234.
- Rai K.R. A critical analysis of staging in CLL. In: Gole R.P., Rai K.R., eds. Chronic Lymphocytic Leukemia. Recent Progress and Future Directions Alan R. Liss. New York 1987, pp. 253−264.
- Rassenti L.Z., Kipps T.J.Clinical utility of Assessing ZAP-70 and CD38 in Chronic Lymphocytic Leukemia. Clinical Cytometry 2006, vol. 70, pp. 209−213.
- Rawstron A.C., Green M.J., Kuzmicki A. et al. Monoclonal Π lymphocytes with the characteristics of «indolent» chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002, vol. 100(2), pp. 635−639.
- Rawstron A.C., Yuille M.R., Fuller J. et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood 2002, vol. 100, pp. 2289−2291.
- Rawstron A.C., Bennett F., Hillmen P. et al. The biological and clinical relationship between CD5+23+ monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. Br J Haematology 2007, vol. 139(5), pp. 724−729.
- Relly J.T. Haematological problems in elderly patients an update. Reviews in Clinical Gerontology 1998, vol. 8, pp. 141−154.
- Rosati S., Kluin P.M. Chronic lymphocytic leukemia: a review of the im-muno architecture. Curr Top Microbiol Immunol 2005, vol. 294, pp. 91−107.
- Rosenwald A., Alizaden A.A., Widhopf G. et al. Relation of gene expression phenotype to immunological mutation genotype in Π cell chronic lymphocytic leukemia. J Exp Med 2001, vol. 194, pp. 1639−1647.
- Rossi D., Zucchetto A., Ross F.M. et al. CD49d expression is an independent risk factor of progressive disease in erly stage chronic lymphocytic leukemia. Haematologica 2008, vol. 93, pp. 1575−1579.
- Rozman C., Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995, vol. 333(22), pp. 1052−1057.
- Sagaert X., Sprangers Π., De Wolf-Peeters. The dinamics of the Π follicle: understading the normal counterpart of B-cell-derived malignancies. Leukemia 2007, vol. 21, pp. 1378−1386.
- Santelises A.M., Mellstedt H., Jondal M. Leukemic cell from progressive B-cell respond strongly to growth stimulation in vitro. Leukemia 1994, vol. 8(7) pp. 1146−1152.
- Sarasua S.M., Vogt R.F., Middleton D.C. et al. CLL-Like B-Cell Pheno-types Detected in Superfund Studies: Epidemiologic Methods and Findings. In:
- Sarmiento M.A., Palacios M.F., Scolnic M.P. et al. Evolution of chronic lymphocytic leukemia: predictive value of immunophenotype soluble CD23 and morphology. Medicina 2002, vol. 62(4), pp. 305−312.
- Schwarz J., Mikulenkova D., Cermakova K. et al. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVh gene mutational status and other prognostic markers. Blood 2006, vol. 53(3), pp. 219−225.
- Sellic G.S., Goldin L.R., Wild R.W. et al. A high density SNP genome -wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood 2007, vol. 110, pp. 3326−3333.
- Seyfried I., Hofbouer S., Stoecher M. et al. SNP 309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutrilin-3a. Blood 2008, vol. 112(5), p. 2168.
- Sgambati M.T., Linet M.S., Devesa S.S. et al. Epidemiological, familial, and genrtic aspects. In: Cheson B.D., ed. Chronic lymphid leukemias 2nd ed. Marsel Dekker NY 2001, pp. 33−62.
- Shanafelt T.D., Lin Π’., Geyer S.M. Pentostatin, cyclophosphamid and riuximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007, vol. 109, pp. 2291−2298.
- Shanafelt T.D., Geyer S.M., Bone N.D. et al. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukemia: a prognostic parameter with therapeutic potential. Br J Haematol 2008, vol.140, pp. 537−546.
- Shanafelt Π’., Kay N.E., Jeankins G. et al. B-cell Count and Survival: Differentiating Chronic Lymphocytic Leukemia (CLL) from and Monoclonal B-cell Lymphocitosis (MBL) based on clinical outcome. Blood 2008, vol. 112, abstr. 2062.
- Shroens R., Griesinger F., Trumper L. et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005, vol. 19, pp. 750−758.
- Sthoeger Z., Sthoeger D., Shtalrid M. et al. Mechanism of autoimmune hemolytic anemia in chronic lymphocytic leukemia. Am J Hematol 1993, vol. 43, pp. 259−264.
- Stramatopoulos Π., Haibe-Kains Π., Eqveter C. et al. Gene expression profiling based on ZAP-70 mRNA expression reveals differences in microevironment interaction between patients with good and poor prognosis. Haematologica 2009, vol. 94, pp. 790−794.
- Struski S., Leymarie V., Helios C. et al. A cytological, immunophenotypical and cytogenetical study of 136 consecutive cases of B-cell chronic lymphoid hemopathies. Pathol Biol (Paris) 2007, vol. 55(1), pp. 59−72.
- Tam C.S., O’Brien S., Wierda W. et al. Long-term results of the fludara-bine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, vol. 112 (4), pp. 975−980.
- Tamura K., Sawada H., Izumi Y. et al. Kyushy Hematology Organization for Treatment (K HOT) study Group. Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T — CLL is high in Japan. Eur J Haematol 2001, vol. 67, pp. 152−157.
- Terrin L., Trentin L., Degan M. et al. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival ad delineate subgroups of patients with the same Ig VH mutation status and different outcome. Leukemia 2007, vol. 21, pp. 965−972.
- Thornton P.D., Fernandez C., Clustolisi G.M. et al. CD38 expression as a prognostic indicator in chronic lymphocytic leukemia. The Hematology Journal 2004, vol. 5, pp. 145−151.
- Tobin G., Thunberg V., Laurell A. et al. Patients with chronic lymphocytic leukemia with mutated VH genes, presenting with Binet stage Π or Π‘ form a subgroup with a poor outcome. Haematologica 2005, vol. 90(4), pp. 465-^69.
- Tonino S.H., Spijker R., Dieuwentje M.P. et al. No convincing evidence for a role of CD31 CD38 interactions in the pathogenesis of chronic lymphocytic leukemia. Blood 2008, vol. 112, pp. 840−843.
- Totterman Π’.Π., Carlsson M., Simonsson B. et al. T-cell activation and subset pattern are altered in B-cell and correlated with the stage of the disease. Blood 1989, vol. 74, pp. 789−782.
- Utterback D.F., Rinslcy R.A., Benzene exposure assessment in rubber hydrochloride workers: a critical evaluation of previous estimates. Am J Ind Med 1995, vol. 27, pp. 661−667.
- Vonura K., Trang Le, Esterbauer H. et al. Autoimmune conditions andchronic infections in chronic lymphocytic leukemia patients at diagnosis are assoti-ated with unmutated IgVH genes. Haematologica 2008, vol. 93, pp. 1912−1916.
- Vuiller F., Tortovoye P., Binet J.L. et al. CD4, CD8 and NK subsets in B-CLL. Nouv Rev Fr Hematol 1988, vol. 30, pp. 333−334.
- Watanabe Π’., Hotta Π’., Ichikawa T. et al. The MDM2 oncogene overex-pression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994, vol. 84(9), pp. 3158−3165.
- Watanabe Π’., Ichikawa Π’., Saito H. et al. Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leukemia and Lymphoma 1996, vol. 21, pp. 391−397.
- Weinberg J.Π., Volkheimen A.D., Chen Y. et al. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. American Journal of Hematology 2007, vol. 82, pp. 1063−1070.
- Wilson J.D., Nossel G.J.V. Identification of human T and Π lymphocytes in normal peripheral blood and in chronic lymphocytic leukemia. Lancet 1971- ii: 788−791.
- Wojciech G. Chromosomal aberrations. In: Prognostic Marcers in Hematologic Oncology. Taylor & Francis Oxon, UK 2006, pp. 49−76.
- Xie J., Wang Y., Freeman M.E. et al. P2 -microglobulin as a negativeregulator of immune system: high concentration of the protein inhibit in vitro generation of functional dendritic cells. Blood 2003, vol. 101(10), pp. 4005−4012.
- Yuille M.R. Houlston R.S., Catovsky D. Anticipation in familial chronic lymphocytic leukemia. Leukemia 1998, vol. 12, pp. 1696−1698.
- Yuille M.R., Matutes E., Marossy A. et al. Familial chronic lymphocyticleukemia: a survey and rewiew of publised studies. Br J Haematol 2000, vol. 109(4), pp. 794−799.
- Zakinoen S., Kay N. Immunoregulatory cell dysfunction in chronic B-cell leukemias. Blood Rewiev 1990, vol. 4, pp. 165−174.
- Zent C.S., Ding W., Schwagen S.M. et al. The prognostic Significance of Cytopenia in CLL/ Small Lymphocytic Lymphoma (SLL). Br J Haematol 2008, vol. 141(5), pp. 615−621.
- Ziegler M. New functions of long known molecule. European journal of Biochemistry 2000, vol. 267(6), pp. 1550−1564.
- Zupo S., Isnardi L., Megna M. et al. CD38 expression distingvishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti Ig M antibodes and propensity to apoptosis. Blood 1996, vol. 88(4), pp. 1365−1374.
- Zupo S., Massara R., Dono M. et al. Apoptosis of plasma cell differentiation of CD38-positive B-Chronic lymphocytic leukemia cell induced by cross-lynking of surfase Ig M or Ig D. Blood 2000, vol. 95(4), pp. 1196−1206.